Esperion Therapeutics

Esperion Completes Patient Enrollment in the Global CLEAR Cardiovascular Outcomes Trial for Bempedoic Acid

Retrieved on: 
Giovedì, Settembre 5, 2019
Cardiovascular disease, RTT, Esperion Therapeutics, Nutrition, Health, Diets, Cardiovascular diseases, Hepatotoxins

ANN ARBOR, Mich., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced the completion of patient enrollment in the CLEAR Cardiovascular Outcomes Trial.

Key Points: 
  • ANN ARBOR, Mich., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced the completion of patient enrollment in the CLEAR Cardiovascular Outcomes Trial.
  • Completing enrollment in CLEAR Outcomes is an important milestone in the clinical development of bempedoic acid.
  • The CLEAR Cardiovascular Outcomes Trial builds on these results and will determine whether bempedoic acid can also reduce the risk of cardiovascular morbidity and mortality.
  • CLEAR Outcomes is a Phase 3, event-driven, randomized, multicenter, double-blind, placebo-controlled trial designed to evaluate whether treatment with bempedoic acid reduces the risk of cardiovascular events.

Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter Financial Results

Retrieved on: 
Giovedì, Agosto 8, 2019
Lipids, Branches of biology, Medical specialties, Bempedoic acid, ATP citrate lyase, Esperion Therapeutics, Low-density lipoprotein, Cholesterol, Citrate (pro-3S)-lyase

ANN ARBOR, Mich., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided bempedoic acid franchise development program updates and financial results for the second quarter ended June 30, 2019.

Key Points: 
  • ANN ARBOR, Mich., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided bempedoic acid franchise development program updates and financial results for the second quarter ended June 30, 2019.
  • Already in 2019, we completed precedent setting agreements with Daiichi Sankyo Europe and Oberland Capital which validated the economic value of the global bempedoic acid franchise.
  • We also achieved the filing and acceptance of New Drug Applications in the US and Marketing Authorization Applications in the EU for both bempedoic acid and the bempedoic acid / ezetimibe combination tablet, said Tim M. Mayleben, president and chief executive officer of Esperion.
  • Inhibition of ATP Citrate Lyase (ACL) by bempedoic acid reduces cholesterol biosynthesis and lowers LDL-C by up-regulating the LDL receptor.

Esperion to Present at the BTIG Biotechnology Conference

Retrieved on: 
Martedì, Agosto 6, 2019
Lipids, Medical specialties, Branches of biology, Cardiology, Lipoproteins, Bempedoic acid, Low-density lipoprotein, Statin, ATP citrate lyase, Cholesterol, Esperion Therapeutics

ANN ARBOR, Mich., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announcedthat the company will participate in a lipid panel discussion with investors at the BTIG Biotechnology Conference in New York, NY on Monday, August 12, 2019 at 11:00 a.m. Eastern Time.

Key Points: 
  • ANN ARBOR, Mich., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announcedthat the company will participate in a lipid panel discussion with investors at the BTIG Biotechnology Conference in New York, NY on Monday, August 12, 2019 at 11:00 a.m. Eastern Time.
  • Similar to statins, bempedoic acid also reduces hsCRP, a key marker of inflammation associated with cardiovascular disease.
  • Inhibition of ATP Citrate Lyase (ACL) by bempedoic acid reduces cholesterol biosynthesis and lowers LDL-C by up-regulating the LDL receptor.
  • Esperion is the Lipid Management Company passionately committed to developing and commercializing convenient, cost-effective, complementary, once-daily, oral therapies for the treatment of patients with elevated LDL-C.

Biotech Stocks: Why Expensive U.S. Drug Trials are Pushing Pharma Research Overseas

Retrieved on: 
Martedì, Maggio 7, 2019
Esperion Therapeutics, NASDAQ, Economy of the United States, Companies, Finance, NASDAQ Biotechnology Index

The more time you spend, the more money you're burning; we look for every opportunity to shorten the pathway.

Key Points: 
  • The more time you spend, the more money you're burning; we look for every opportunity to shorten the pathway.
  • "Active biotech and pharma companies in the markets this week include Moleculin Biotech, Inc. (NASDAQ:MBRX), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), Athenex, Inc. (NASDAQ: ATNX), TherapeuticsMD, Inc. (NASDAQ: TXMD).
  • The insider went on to provide some other reasons, in addition to lower costs, that the E.U.
  • You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.

Biotech Stocks: Why Expensive U.S. Drug Trials are Pushing Pharma Research Overseas

Retrieved on: 
Martedì, Maggio 7, 2019
Esperion Therapeutics, NASDAQ, Economy of the United States, Companies, Finance, NASDAQ Biotechnology Index

The more time you spend, the more money you're burning; we look for every opportunity to shorten the pathway.

Key Points: 
  • The more time you spend, the more money you're burning; we look for every opportunity to shorten the pathway.
  • "Active biotech and pharma companies in the markets this week include Moleculin Biotech, Inc. (NASDAQ:MBRX), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), Athenex, Inc. (NASDAQ: ATNX), TherapeuticsMD, Inc. (NASDAQ: TXMD).
  • The insider went on to provide some other reasons, in addition to lower costs, that the E.U.
  • You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.

Daiichi Sankyo Europe Enters into European Licensing Agreement with Esperion for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet

Retrieved on: 
Lunedì, Gennaio 7, 2019
Merck, Medicine, Esperion Therapeutics, Schering-Plough, Chemistry, Health, Ezetimibe, Statin, Daiichi Sankyo, Cholesterol, Low-density lipoprotein

Bempedoic acid is a first-in-class,oral, once-daily ATP Citrate Lyase (ACL) inhibitorthatreduces cholesterol and fatty acidsynthesis in the liver[1]

Key Points: 
  • Bempedoic acid is a first-in-class,oral, once-daily ATP Citrate Lyase (ACL) inhibitorthatreduces cholesterol and fatty acidsynthesis in the liver[1]
    This agreement expands Daiichi SankyoEurope's commitment to cardiovascular care and the development of innovative, convenientandaffordabletreatments
    Daiichi Sankyo Europe has entered into an exclusive licensing agreement with Esperion Therapeutics (NASDAQ: ESPR) for Daiichi Sankyo Europe to market bempedoic acid and bempedoic acid / ezetimibe combination tablet in the European Economic Area and Switzerland.
  • Daiichi Sankyo Europe will be responsible for commercialization in these territories while Esperion will be responsible for the development and manufacturing.
  • Esperion completed its Phase 3 LDL-C development program of bempedoic acid and bempedoic acid / ezetimibe combination tablet in October 2018.
  • Through the complementary mechanisms of action of inhibition of cholesterol synthesis (bempedoic acid) and inhibition of cholesterol absorption (ezetimibe), the bempedoic acid / ezetimibe combination tablet is a non-statin, orally available, once-daily, LDL-C lowering therapy.